Previous 10 | Next 10 |
TransMedics has seen continued progress in the business, mostly on the research front. The pandemic is still halting revenue growth as more approvals and lifting of restrictions might drive growth from here. I like the long-term potential, driven by product superiority, as still s...
The shares of medical device makers have come under pressure in morning hours after Texas Governor Greg Abbott encouraged the hospitals to consider postponing certain elective medical procedures to make room for rising COVID-19 patients in the state. The seven-day average of COVID-19 hospital...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ANDOVER, Mass. , Aug. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant th...
TransMedics Group, Inc. (TMDX) Q2 2021 Earnings Conference Call August 5, 2021 04:30 PM ET Company Participants Brian Johnston - Vice President, Investor Relations Waleed Hassanein - President & Chief Executive Officer. Stephen Gordon - CFO, Treasurer & Secretary Conference Call Parti...
TransMedics Group (NASDAQ:TMDX): Q2 GAAP EPS of -$0.39 misses by $0.10. Revenue of $8.2M (+141.9% Y/Y) beats by $0.65M. Gross margin for the second quarter of 2021 was 68% as compared to 56% in the second quarter of 2020. Cash, cash equivalents and marketable securities were $112.2 million as...
TransMedics Reports Second Quarter 2021 Financial Results PR Newswire ANDOVER, Mass. , Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patient...
TransMedics Group (NASDAQ:TMDX) announces FDA 510(k) clearance of its OCS Lung Solution for use in transplants using cold storage techniques. TMDX shares up 2.9% premarket at $30.04. The solution, which is also cleared as a component of the company's OCS Lung System, is indicated for hypother...
TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs TransMedics to Provide The Most Comprehensive Lung Preservation Product Portfolio to Lung Transplantation Centers in the U.S. PR Newswire ANDOVER, Mass. , July 29, 20...
TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference PR Newswire ANDOVER, Mass. , July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ trans...
TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire ANDOVER, Mass. , July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ t...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...